VS-1
Acute post-operative pain following Total Knee Arthroplasty (TKA)
Phase 2aActive
Key Facts
Indication
Acute post-operative pain following Total Knee Arthroplasty (TKA)
Phase
Phase 2a
Status
Active
Company
About Vitalis
Vitalis Therapeutics is a private, pre-revenue biotech company founded in 2019, developing VS-1, an oral ketamine solution for acute post-operative pain. The company is preparing for a Phase 2a clinical trial in total knee replacement patients, aiming to provide a non-opioid option that reduces addiction risk and side effects while potentially accelerating recovery. Led by physician-researchers, Vitalis leverages regulatory agility and aims to address a significant unmet need within the context of the opioid crisis, targeting a large and growing surgical market.
View full company profile